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Abstract
The urea cycle converts toxic ammonia to urea within the liver of mammals. At least 6 enzymes are required for ureagenesis,
which correlates with dietary protein intake. The transcription of urea cycle genes is, at least in part, regulated by
glucocorticoidand glucagonhormone signalingpathways.N-acetylglutamatesynthase(NAGS)producesauniquecofactor,N-
acetylglutamate (NAG), that is essential for the catalytic function of the first and rate-limiting enzyme of ureagenesis, carbamyl
phosphate synthetase 1 (CPS1). However, despite the important role of NAGS in ammonia removal, little is known about the
mechanisms of its regulation. We identified two regions of high conservation upstream of the translation start of the NAGS
gene. Reporter assays confirmed that these regions represent promoter and enhancer and that the enhancer is tissue specific.
Within the promoter, we identified multiple transcription start sites that differed between liver and small intestine. Several
transcription factor binding motifs were conserved within the promoter and enhancer regions while a TATA-box motif was
absent. DNA-protein pull-down assays and chromatin immunoprecipitation confirmed binding of Sp1 and CREB, but not C/
EBP in the promoter and HNF-1 and NF-Y, but not SMAD3 or AP-2 in the enhancer. The functional importance of these motifs
was demonstrated by decreased transcription of reporter constructs following mutagenesis of each motif. The presented data
strongly suggest that Sp1, CREB, HNF-1, and NF-Y, that are known to be responsive to hormones and diet, regulate NAGS
transcription. This provides molecular mechanism of regulation of ureagenesis in response to hormonal and dietary changes.
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Introduction
Ammonia, the toxic product of protein catabolism, is converted
to urea by the urea cycle in the liver of mammals. Incorporation of
two nitrogen atoms into urea is catalyzed by six enzymes: three of
them mitochondrial, N-acetylglutamate synthase (NAGS; EC
2.3.1.1), carbamylphosphate synthetase 1 (CPS1; EC 6.4.3.16)
and ornithine transcarbamylase (OTC; EC 2.1.3.3), and the other
three cytosolic, argininosuccinate synthetase (ASS; EC 6.3.4.5),
argininosuccinate lyase (ASL; EC 4.3.2.1) and arginase 1 (Arg1;
EC 3.5.3.1).
NAGS catalyzes the formation of N-acetylglutamate (NAG), an
essential allosteric activator of CPS1, in the mitochondrial matrix
of hepatocytes and small intestine epithelial cells [1,2]. Within
hepatocytes, NAGS activity and NAG abundance are regulated by
L-arginine, ammonia, and dietary protein intake [3,4,5] and
therefore, the NAGS/NAG system may play a critical role in the
regulation of ureagenesis in response to these factors [6]. While
studies in the 1980s and 1990s identified the cis-acting motifs
regulating transcription of the urea cycle enzymes CPS1
[7,8,9,10], OTC [11,12,13,14], ASS [15,16,17], ASL [18,19,20],
and Arg1 [21,22], the mammalian NAGS gene was not identified
until 2002 [2] and we can now report for the first time on its
transcriptional regulation.
Many studies have identified regulatory links between the urea
cycle genes and glucocorticoids and glucagon [23,24,25], however
the mechanism of regulation differs for each gene [24,26,27,28,29].
Transcription of CPS1 is activated by TATA-binding protein (TBP)
while its proximal and distal enhancers contain binding sites for
glucocorticoids and cAMP responsive factors including CCAAT-
enhancer bind protein (C/EBP), activator protein-1 (AP-1),
glucocorticoid receptor (GR) and cAMP response element binding
(CREB). Sites for binding tissue specific factors including hepatic
nuclear factor 3 (HNF-3) are also present [25,30,31]. Tissue specific
expression of the OTC gene is induced in the intestine and liver by
HNF-4, which binds in the promoter [13,14,32] while binding of
both HNF-4 and C/EBP to the enhancer, induces high expression
levels in the liver [12,13,14,25,33]. ASS transcription is regulated by
cooperative binding of multiple specificity protein 1 (Sp1)
[16,34,35,36]. ASL is regulated through Sp1 and the positive
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of ASL to activate its transcription [18,19,20,37]. Sp1 and nuclear
factor 1 (NF-1)/CCAAT-binding transcription factor (CTF)
activate ARG1 transcription while two C/EBP factors and two
unidentified proteins bind within an enhancer in intron 7 to confer
glucocorticoid responsiveness [22].
Abundance of urea cycle enzymes correlates with dietary protein
intake [3,28]. Transcription of urea cycle genes is in part regulated by
the glucocorticoid and glucagon signaling pathways [29,38]. There-
fore, we postulate that there exists a nitrogen sensing mechanism that
is both responsive to amino acid(s) and hormone stimulation and that
an understanding of the transcriptional regulation of NAGS could
contribute to the understanding of such mechanism.
In this study, we identified two regulatory regions upstream of
the NAGS translation start site that contain highly conserved
protein-binding DNA motifs. We subsequently confirmed that
these regions function as promoter and enhancer and that the
enhancer is most effective in liver cells. Avidin-agarose protein-
DNA pull-down assays have been used to confirm binding of Sp1
and CREB within the NAGS promoter and Hepatic Nuclear
Factor 1 (HNF-1) and NF-Y within the enhancer regions.
Chromatin immunoprecipitation (ChIP) and quantitative real-
time PCR have been used to independently verify that Sp1 and
CREB bind to the promoter region, and HNF-1 and NF-Y bind to
the enhancer region. We also used 59RACE analysis to identify
multiple transcription start sites for NAGS that may be species and
tissue specific. These findings provide new information on the
regulation of the NAGS gene, and suggest possible mechanisms for
coordinated regulation of the genes involved in ureagenesis.
Materials and Methods
Bioinformatic Analysis of the Upstream Regulatory
Regions
Pair-wise Alignment Analysis. Identification of highly
conserved regions was conducted by gathering 15 kilobases of
genomic sequence 59 of the NAGS translational start site and
sequence of intron one in 7 mammalian species including: human
(NM_153006.2), chimpanzee (XM_001152480.1), dog (XM_
548066.2), cow (XM_618194.4), horse (XM_001917302.1), mouse
(NM_145829.1) and rat (NM_001107053.1). The highly conserved
regulatory regions of CPS1 were identified by gathering 15 kilobases
of genomic sequences 59 of the translational start site from human
(NM_001875), chimpanzee (XM_001146604), dog (XM_856862),
mouse (NM_001080809), and rat (NM_017072). Genomic se-
quences were subject to pair-wise comparison using BLAST bl2seq
tool [39]. Parameters included expect threshold of 10, match and
mismatch scores of 1 and 22, respectively, gap existence and
extension scores of 5 and 2 respectively, and maximum expected
value E=0.001. Regions of high conservation were identified as
sequences with more than 80% identity that were at least 100 bp
long and present in four or more species.
Cis-eLement OVERrepresentation (CLOVER) Analysis.
The Cis-element OVERrepresentation (CLOVER) [40] program
was used to predict the over-represented motifs within the highly
conserved regulatory regions of NAGS and CPS1. CLOVER analysis
of these conserved regions identified known protein binding DNA
motifs in the TRANSFAC Pro database by calculating over-
representation of these sequences compared to a background of
ppr_build_33.fa generated from NCBI build 33 [41]. Matrices
recognized by multiple transcription factors in the same family are
represented by one family member unless otherwise noted. Genomic
sequences of the highly conserved regions were aligned using
CLUSTALW version 2.0.10 [42].
Plasmid Constructs
The promoter and enhancer of NAGS, were amplified from
human genomic DNA with primer pairs hPromXH and hEnhXH
or hPromHXrev and hEnhHXrev (Table S1), respectively, to
introduce XhoI and HindIII restriction enzyme sites and allow
subcloning in forward and reverse orientation. Platinum Taq
PCRx DNA Polymerase (Invitrogen) was used for amplification
with the following conditions: initial denaturation at 95uC for
2 min., followed by 35 cycles of denaturation at 95uC for 30 sec.,
annealing at 57uC for 30 sec. and extension at 68uC for 1 min.,
and final extension at 68uC for 6 min. Promoter and enhancer
PCR products were ligated with TOPO-TA sequencing vector
(Invitrogen) according to manufacturer’s instructions and referred
to as TOPOProm, TOPOEnh, TOPOPromRev, and TOPOEnh-
Rev, respectively. Mouse Nags (mNags) promoter and enhancer
were inserted into TOPO-TA vector following the same methods.
Correct DNA sequences were confirmed using sequencing primers
specified by Invitrogen.
TOPOProm, TOPOEnh, TOPOPromRev, TOPOEnhRev,
pGL4.10 (Promega) basic vector containing firefly (Photinus pyralis)
luciferase luc2, and pGL4.23 (Promega) vector containing a
minimal TATA promoter with luc2 were cut with XhoI (New
England Biolabs) and HindIII (New England Biolabs). The vectors
were treated with Antarctic Alkaline Phosphatase (AAP) (New
England Biolabs) according to manufacturer’s instructions, and the
NAGS regions were ligated with the vectors to form the plasmids in
Table 1. TOPOEnh was also amplified with primer pair hEnhBS
(Table S1), to introduce BamHI and SalI restriction enzyme sites at
the 59 and 39 ends of the enhancer, respectively. The amplified
enhancer product and 4.10Prom were cut with BamHI (New
England Biolabs) and SalI (New England Biolabs), the vector was
treated with AAP, and the enhancer was ligated with the vector
(Table 1). Plasmids containing mouse NAGS promoter and
enhancer were generated using the same methods with the primer
pairs listed in Table S1 and plasmids in Table 1. Correct
sequences were confirmed using primers specified by Promega.
Point mutations in the binding sites for transcription factors
Sp1, HNF-1 and NF-Y were selected based on functional analysis
Table 1. Plasmids generated for luciferase reporter assays.
Name Vector Insert
4.10Prom pGL4.10 hNAGS promoter
4.10Enh pGL4.10 hNAGS enhancer
4.23Enh pGL4.23 hNAGS enhancer
4.10PromEnh 4.10Prom hNAGS enhancer
4.10PromRev pGL4.10 hNAGS promoter reverse
4.23EnhRev pGL4.23 hNAGS enhancer reverse
m4.10Prom pGL4.10 mNAGS promoter
m4.10Enh pGL4.10 mNAGS enhancer
m4.23Enh pGL4.23 mNAGS enhancer
m4.10PromEnh 4.10Prom mNAGS enhancer
4.10Sp1m pGL4.10 hNAGS promoter with Sp1 mutations
4.10CREBm pGL4.10 hNAGS promoter with CREB mutations
4.23HNF-1m pGL4.23 hNAGS enhancer with HNF-1 mutations
4.23NF-Ym pGL4.23 hNAGS enhancer with NF-Y mutations
Human or mouse promoter or enhancer were ligated with pGL4 vectors for use
with luciferase reporter assays.
doi:10.1371/journal.pone.0029527.t001
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other genes. Mutations were engineered by Integrated DNA
Technologies and provided in pIDTSMART-KAN vectors (IDT)
(Table 2). Plasmids with mutant Sp1, HNF-1, and NFY were cut
with XhoI and HindIII. Reporter plasmids pGL4.10, and pGL4.23
were cut with XhoI and HindIII and treated with AAP. Mutated
inserts were ligated with vectors to form the plasmids 4.10Sp1m,
4.23HNF-1m, and 4.23NFYm (Table 1). Correct sequences were
confirmed using primers specified by Promega.
Point mutations in the CREB binding site, c.-7T.C and c.-
5T.A (Table 2), were selected based on functional analysis of
CREB binding [50,51] in other genes and were engineered into
the NAGS gene using QuickChange Lightening Site-Directed
Mutagenesis Kit (Agilent) according to manufacturer’s instruc-
tions. Primers hCREBm Fw and Rv (Table S1) amplified 50 ng of
template plasmid 4.10Prom to create 4.10CREBm. The correct
sequence was confirmed using primers specified by Promega.
The expression vectors encoding Sp1 or HNF-1 cDNA were
under control of the cytomegalovirus promoter (Origene).
Tissue culture
Cell culture and transfection. Human hepatoma cells
(HepG2) (donated by Dr. Marshall Summar, Children’s National
Medical Center, Washington, DC) were cultured in complete media
containing RPMI 1640 medium (Invitrogen) supplemented with 10%
fetal bovine serum (FBS) (ATCC) and 5% Penicillin/Streptomycin
(Invitrogen) under 5% CO2 at 37uC. Human alveolar basal epithelial
cells (A549) (donated by Dr. Mary Rose, Children’s National Medical
Center, Washington, DC) were cultured in complete media
containing Ham’s F-12 medium (Invitrogen) supplemented with
10% FBS and 5% Penicillin/Streptomycin. Human colorectal
adenocarcinoma cells (Caco-2) (ATCC) were cultured in Eagle’s
Minimum Essential Medium (Invitrogen) supplemented with 20%
FBS. Cells were plated at a density of 5610
5 cells/well on 24-well
culture plates 24 hours prior to transfection. The cells (90–95%
confluent for HepG2 and A549, 80–85% confluent for Caco-2) were
then transfected using Lipofectamine 2000 reagent (Invitrogen) and
cultured in transfection media containing medium and serum only. A
total of 0.25 ug of DNA was transfected with 0.225 ug of vector
expressing luc2 and 0.025 ug of pGL4.74 vector containing Renilla
reniformis luciferase (hRluc) as an internal control (Promega). For co-
transfections 0.225 ug of luc2 vector was combined with either
0.25 ug of expression vector or empty vector pUC19 (Invitrogen),
and 0.025 ug of hRluc control vector.
Reporter assays
24 hours following transfection, cells were assayed for both
firefly and Renilla luciferase activity using Dual-Luciferase
Reporter Assay System (Promega) and Berthold Centro 960
luminometer (Berthold) according to the manufacturer’s protocol.
All reporter assay measurements were corrected for transfection
efficiency by normalizing the firefly luciferase signal to the Renilla
luciferase values. Expression level of each construct was deter-
mined relative to luciferase expression under control of the NAGS
promoter in each cell line. All results are an average of three
independent experiments that were each carried out in triplicate.
Values were expressed as mean 6 SEM and analyzed using
Student’s t-test.
59 Rapid Amplification of cDNA Ends (RACE)
59 RACE (Version 2.0; Invitrogen) was performed using RNA
isolated from donated mouse livers by Trizol reagent (Invitrogen).
RNA from mouse small intestine (Origene), human duodenum
(Ambion), or human liver (Ambion) was commercially available.
Products were synthesized with human or mouse NAGS specific
primers complementary to sequence within Exon 1 (Table S2). All
reactions began with 5 ug of total RNA and the RACE procedure
was conducted according to manufacturer’s instructions. Second
strand synthesis was conducted using Ex Taq Polymerase
(TaKaRa Bio Inc.) PCR products were subcloned into pCR 2.1-
TOPO vector (Invitrogen) and RACE products were sequenced
with primers specified by the manufacturer.
Avidin-Agarose DNA-Protein Pull-Down Assay
Biotinylated DNA probes. Probes for Avidin-Agarose DNA-
Protein Pull-Down Assays were generated by PCR amplification of
genomic DNA isolated from donated mouse tails using Pure Gene
DNA Purification Kit (Gentra). Probes were generated using
biotinylated or non-biotinylated forward primer and non-
biotinylated reverse primers with Platinum Taq PCRx DNA
Polymerase (Invitrogen) and amplification conditions: initial
denaturation at 95uC for 2 min., followed by 35 cycles of
denaturation at 95uC for 30 sec., annealing at 60uC for 30 sec.
and extension at 68uC for 1 min., and final extension at 68uC for
6 min. The mouse Nags (mNags) promoter regions A and B
(Figure 1) were amplified with primer pair mNAGS-Prom Region
A, from +97 to 2259, relative to the translation initiation codon
and with mNAGS-Prom Region B, from 2302 to 2776,
respectively (Table S3). A region of mNags, that is not highly
conserved in mammals, 21056 to 21320, was amplified using
primer pair mNAGS-Prom-NC to serve as a negative control for
the promoter regulatory region. The enhancer region of mNAGS,
spanning from 22834 to 23167, was amplified using forward
primer pair mNAGS-enh. The negative control for the enhancer
region, a non-conserved region located close to enhancer, was the
amplification product of primer pair mNAGS-Enh-NC spanning
25569 to 25997 upstream of mNags. Additional negative controls,
non-biotinylated probes, were generated using each primer pair.
Preparation of nuclear extracts. Nuclear extract was
isolated from donated adult mouse livers of C57BL/6 mice
using Nuclear Extraction Kit (Origene) according to
manufacturer’s instructions. The protein concentration of the
nuclear extract was determined using bovine serum albumin as the
protein standard with Bradford Assay dye concentrate reagents
(Bio-Rad). On average, 10 mg of nuclear protein was obtained
from mouse liver.
Binding Protocol and Western Blot. For the avidin-agarose
protein-DNA pull-down assay [52], 1 mg of nuclear extract in PBS
buffer containing inhibitors (PBSI; 16 PBS with 0.5 mM PMSF,
Table 2. Mutations in Sp1 and CREB binding sites in the
promoter, and HNF-1 and NF-Y in the enhancer of human
NAGS.
Factor Wild-type Mutant
Sp1 59-CCGCCCCCGCC-39 59-AAGAACAAGAA-39
59-GGGGCGGGGG-39 59-GGTTCTTTGG-39
59-CCCCGCCCCC-39 59-CCAAGAAACC-39
59-CCCCGCCCCG-39 59-CCAAGAAACG-39
CREB 59-GGTTGTCGTCATGG-39 59-GGTCGACGTCATGG-39
HNF-1 59-TGGAGTTAATCATCTACTCTG-39 59-TGGAGTAAGTCTGCAACCAGG-39
NF-Y 59-GGCCCCATTGGCTGCCT-39 59-GGCCCCTCCAGCTG-39
doi:10.1371/journal.pone.0029527.t002
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avidin-agarose beads (Sigma) were combined and incubated for
16 hrs on a rotating shaker at 4u. The probe and bead
concentrations were in excess to ensure complete pull-down of
DNA–protein complexes. Following incubation, the supernatant
was reserved while the beads were washed 3 times with cold PBSI
and then resuspended and boiled in Laemmli protein denaturing
buffer (Bio-Rad) with 0.2 M DTT. The supernatant was also
combined with denaturing buffer with DTT and boiled; all samples
were loaded onto 10% SDS–polyacrylamide gel. The proteins were
separated by electrophoresis, transferred to a nitrocellulose
membrane, and then identified by immunoblotting using primary
antibodies at 1:2000 dilution of antibody to Sp1 (Santa Cruz
Biotech; Millipore), 1:1000 dilution of CREB-1a/b (Santa Cruz
Biotech), and 1:3000 dilution of C/EBPa/b (Santa Cruz Biotech)
for the promoter region and 1:500 dilution of HNF-1a/ß (Santa
Cruz Biotech), 1:1000 dilution of NF-Ya (Santa Cruz Biotech) and
1:2000 dilution of SMAD2/3 (Santa Cruz Biotech) for the 23k b
conserved region. The membrane was than incubated with
1:20,000 dilution of donkey anti-rabbit secondary antibody
conjugated to horseradish peroxidase (Pierce) and bands were
visualized using SuperSignal West Pico Kit (Pierce) according to
manufacturer’s instructions.
Chromatin Immunoprecipitation
Tissue preparation and DNA immunoprecipitation.
Donated livers from adult C57BL/6 mice were minced and
chromatin was precipitated using SimpleChIP Enzyme Chromatin
Kit (Origene) with the variation for whole tissue. Briefly, fresh
tissue was minced and washed with PBS including Protease
Inhibitor Complete tablets (Roche). Proteins and DNA were cross-
linked with 1.5% formaldehyde, and tissue was disaggregated with
dounce homogenizer. Chromatin was sheared to an approximate
size of 100–1000 bp by micrococcal nuclease digestion followed by
sonication. Immunoprecipitation was conducted using antibodies
to transcription factors Sp1 (Millipore), CREB (Santa Cruz
Biotech), C/EBP (Santa Cruz Biotech), HNF-1 (Santa Cruz
Biotech), NF-Y (Santa Cruz Biotech), SMAD2 (Santa Cruz
Biotech) and AP-2 (Santa Cruz Biotech) and control antibodies
to histone H3 and non-specific rabbit IgG (Cell Signaling
Technologies). Chromatin was eluted from protein G agarose
beads, cross-linking was reversed, and DNA was purified
according to manufacturer’s instructions.
Real-time PCR quantification. ChIP enriched DNA
samples included 2% input control and dilutions for a standard
curve, positive control immunoprecipitate from anti-histone H3
antibody sample, negative control immunoprecipitation from
Figure 1. Regions upstream of the mammalian NAGS genes that are highly conserved. Conservation of mammalian NAGS DNA by
phastCons (green) and phyloP (blue) algorithms is shown with the highly-conserved regions indicated in red boxes (A). Pair-wise blast analysis of
mammalian non-coding regions of NAGS identified highly conserved sequences upstream of the translational start site termed the promoter (purple)
and enhancer (cyan) (B).
doi:10.1371/journal.pone.0029527.g001
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test antibodies. Enriched DNA was subject to quantitative real-time
PCR using iTaq SYBR Green Supermix with ROX (Bio-Rad) and
gene specific primers (Table S4) including negative locus primers to
Chemokine ligand 2 (MIP-2) on a 7900HT Fast Real-Time PCR
System (Applied Biosystems). Amplification conditions included
initial denaturation at 95uC for 2 min., followed by 50 cycles of
denaturation at 95uC for 30 sec., annealing at 60uC for 30 sec. and
extension at 72uC for 30 sec., with dissociation steps of 95u for
15 sec. followed by 50u for 15 sec. and finally 95u for 15 sec.
Samples were amplified and analyzed using 7900HT Sequence
Detection System Software (Applied Biosystems). Values were
expressed as mean 6 SEM and analyzed using Student’s t-test.
Results
Selected regions of non-coding DNA upstream of NAGS
are highly conserved
15 kilobase of genomic DNA sequence 59 of the translational
start site of NAGS and sequence of the first intron from human,
chimpanzee, dog, horse, cow, mouse and rat were aligned and
compared using pair-wise BLAST. Comparisons showed three
highly conserved regions upstream of human NAGS at 257 to
2284, 2498 to 2576, and 22978 to 23344 relative to the start
ATG, and no significant conservation within the intron or
between 25 and 215 kb upstream (Figure 1). The region within
21 kb of the translational start site was designated as the putative
promoter while the region 3 kb upstream was designated a
putative regulatory element. Figure 1 also shows an alignment of
mammalian NAGS genes using phastCons (green) and phyloP
(blue), which identified three non-coding regions of conservation
located 3 kb upstream, immediately upstream, and within the first
intron of NAGS, respectively (Figure 1). The phastCons, phyloP
and our analyses of conservation within the NAGS gene differed
due to different algorithms that were used to identify regions of
conservation [39,53,54].
To validate our strategy for identification of conserved regions,
the same analyses were conducted for CPS1, a gene in which a
proximal promoter and an enhancer element located 6.3 kb
upstream of rat Cps1, have been characterized [55,56,57]. 15 kb of
CPS1 genomic DNA sequence 59 of the translational start site was
collected from human, chimpanzee, dog, mouse and rat and
compared using pair-wise BLAST. Five regions of high conserva-
tion were identified including the previously reported proximal
promoter located immediately upstream of the translation
initiation codon and the enhancer at 27392 to 27966 relative
to ATG of the human CPS1 gene (Figure S1). In addition, three
previously unknown regions, termed A, B and C, were also
identified at 25, 210.5 and 212 kb relative to CPS1 translation
initiation codon (Figure S1). PhastCons and phyloP alignment of
mammalian genomic DNA identified the same 5 conserved
regions (Figure S1).
Highly conserved, non-coding regions of NAGS function
as promoter and enhancer elements for gene
transcription
Reporter assays were used to examine the functionality of each
of the following: wild type NAGS promoter (4.10Prom), control
reversed promoter (4.10PromRev), enhancer alone (4.10Enh),
promoter and enhancer (4.10PromEnh), and enhancer in both
orientations with the heterologous TATA-box promoter (4.23Enh
and 4.23EnhRev) by measuring the expression of a luciferase
reporter gene in cultured HepG2 cells (Figure 2A). Vectors
pGL4.13, pGL4.23, and pGL4.10 containing firefly luciferase luc2,
with an SV40 promoter, a minimal TATA-promoter, or without a
promoter respectively, were used as positive, baseline reference,
and negative assay controls. Vector pGL4.74, containing Renilla
luciferase hRluc, was co-transfected with each plasmid to control
for transfection efficiency.
The human NAGS promoter alone (plasmid 4.10Prom),
stimulated transcription of the luciferase gene while the upstream
regulatory region (plasmid 4.10Enh) alone, did not (Figure 2A).
When the NAGS promoter and upstream regulatory region were
both present (4.10PromEnh plasmid), transcription increased by
50% compared to the promoter alone confirming that the
upstream conserved region can function as an enhancer of
transcription. When the NAGS enhancer was paired with a
heterologous promoter containing a TATA-box, in the 4.23Enh
construct, the transcription of luciferase about three times higher
compared to construct with minimal TATA-box. The backbone
vector 4.10 did not stimulate expression of the luciferase gene. As
expected, positive control vector 4.13, containing a strong
promoter, activated transcription in this cell culture system
(Figure 2A). The promoter in the reverse orientation (4.10Prom-
Rev) did not activate luciferase expression indicating that the
NAGS promoter acts in a direction dependent manner (Figure 2B).
The ability of the NAGS enhancer (4.23EnhRev) to stimulate
transcription with the heterologous promoter was orientation
independent (Figure 2C). Similar results were obtained for
reporter assays using mouse promoter and enhancer (Figure S2).
Transcription of NAGS initiates at multiple sites
Following discovery of the NAGS promoter, the transcriptional
start sites (TSS) in human and mouse liver and small intestine were
identified using 59 RACE (Figure 3A and B). Cloned and
sequenced amplification products from 59RACE were aligned
along the 59 non-coding region of NAGS along with TSS identified
in the Database of Transcriptional Start Sites (DBTSS) and
expressed sequence tags (ESTs) from Genbank. Results suggest
that NAGS has multiple TSS and that some may be species and
tissue-specific. Combined 59RACE, DBTSS, and Genbank results
indicate that within human liver, the most frequently occurring
TSS was at 242 bp upstream of the ATG codon, while in human
small intestine it was at 2146 bp (Figure 3A). Within mouse
tissues, no dominant TSS was evident, but transcription of the
NAGS gene initiated most often from 220 bp and 2108 bp in
liver and 220 bp and 295 bp in small intestine (Figure 3B).
Figure 3 also shows several other rare TSS that were identified.
Transcription factors bind highly conserved motifs within
the promoter and enhancer of NAGS
When promoters and enhancers from six mammalian NAGS
genes were aligned, there were multiple regions of base pair
conservation (Figure 4). Cis-eLement OVER-representation
(CLOVER) software analysis was employed to identify transcrip-
tion factor binding motifs in regulatory regions of human,
chimpanzee, horse, cow, dog, mouse, and rat NAGS. Analyses of
the region +9t o2996 bp (relative to the translational start codon,
promoter, Table S6) and 22866 to 23620 bp (enhancer, Table
S7) predicted several transcription factor binding motifs that are
expressed in the liver, but no TATA-box for transcription
initiation. Sp1 binding sites, within the promoter, and the HNF-
1 binding motif, within the enhancer, received the highest over-
representation scores, but additional motifs with lower scores were
also over-represented.
Next, over-represented motifs were mapped on the CLUS-
TALW alignments (Figure 4A and 4B) and motifs with high
conservation, having been identified in at least four out of the
Regulation of NAGS
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the promoter, five binding sites for Sp1 were highly conserved, two
of which were conserved in all examined species. A binding site
recognized by CREB and Activating Transcription Factor-1
(ATF-1) was conserved in four species and overlapped with the
translation start codon; a C/EBP binding site was identified
farther upstream in region B of the promoter (Figures 4A & 5A).
Within the enhancer, a binding site for HNF-1 was conserved in
all species. Overlapping binding sites for NF-Y, AP-2 and Mothers
Against Decapentaplegic Homolog 3 (SMAD3) were also
conserved in all species, while an additional AP-2 binding site,
located 59 of the HNF-1 site, was conserved in four out of seven
species (Figure 4B & 5B).
To validate computational strategy for identification of
transcription factor binding sites, the enhancers of human,
chimpanzee, dog, mouse, and rat Cps1 were analyzed using
CLOVER, and the experimentally identified binding motifs for
C/EBP, CREB, GR, AP-1 and HNF-3 [55,56,57] were detected
along with additional unreported motifs for HNF-4, AR, C/EBP
and HNF-3 (Figure S3, Table S5). The detection of experimentally
confirmed binding motifs in CPS1 has made the use of CLOVER
for bioinformatic analysis of NAGS credible.
A DNA-protein pull-down assay was devised to test the
bioinformatic prediction of specific binding sites. Two biotin-
labeled DNA probes for the promoter (Figure 5A) encompassed
regions A and B (Lane 1 in Figure 5C) and one probe
(Figure 5B) encompassed the enhancer (Lane 1 in Figure 5D). A
biotinylated probe to a region upstream of the NAGS gene,
lacking any highly conserved motifs (Lane 3 in Figures 5C and
5D), and non-biotinylated probes to region A or B (Lane 2 in
Figures 5C and 5D) were used as negative controls. The
supernatant fluid from each pull-down was included as a
positive control for the presence of the transcription factor
(Lanes 5–8). Intensities of bands corresponding to each
Figure 2. Highly conserved regulatory regions, upstream of the NAGS gene, function as promoter and enhancer elements. In liver
derived cells the NAGS promoter (4.10Prom), promoter+enhancer (4.10PromEnh), enhancer with TATA promoter (4.23Enh), and positive control
promoter vector (pGL4.13) significantly simulate transcription while the enhancer (4.10Enh), basic vector (pGL4.10) does not stimulate transcription
above baseline (A). Reverse insertion of the promoter (4.10PromRev) did not stimulate transcription compared to 4.10Prom and pGL4.10 vector (B),
but reverse enhancer (4.23EnhRev) significantly stimulated transcription compared to 4.23Enh and pGL4.23 vector (C). Calculated results are an
average of three independent experiments that were each carried out in triplicate, normalized to Rluc expression, and expressed relative to the
promoter for each experiment with error reported as 6SEM. Lowercase letters indicate statistically significant differences.
doi:10.1371/journal.pone.0029527.g002
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indicators of pull-down efficiency.
Factors Sp1 and CREB bound to the probe of promoter region
A (Lane 1 in Figure 5C). Sp1 also bound to the probe of promoter
region B (data not shown) while C/EBP did not bind to this probe
(Lane 1 in Figure 5C). Within the enhancer region, transcription
factors HNF-1 and NF-Y bound to the probe, however SMAD2/3
and AP2 did not (Lane 1 in Figure 5D). Binding of Sp1, CREB,
C/EBP, HNF-1, NF-Y, SMAD2/3, and AP-2 was not detected in
the negative controls (Lanes 2–4 in Figures 5C and 5D) while each
transcription factor was detected in the positive controls of liver
nuclear extract supernatants (Lanes 5–8 in Figures 5C and 5D).
Each immunoblot result is representative of at least three replicate
experiments.
Binding of transcription factors to the predicted motifs was also
confirmed using chromatin immunoprecipitation (ChIP) followed
by Real-Time PCR. Measurement compared the enrichment of
target DNA regions to the negative control locus MIP-2. ChIP
with Sp1 and CREB antibodies significantly enriched the NAGS
promoter DNA compared to MIP-2 (p,0.005 and p,0.05,
respectively; Figure 6A). ChIP with C/EBP antibody did not
enrich the NAGS promoter DNA compared to the negative locus
(p.0.05; Figure 6A). The NAGS enhancer was enriched in
chromatin immunoprecipitated with antibodies against HNF-1
and NF-Y (p,0.005 and p,0.05, respectively; Figure 6B), but not
with antibodies against AP-2 and SMAD2/3 (p.0.05; Figure 6B).
Thus, Pull-down and ChIP assays confirmed that Sp1 and CREB
bind along the NAGS promoter and HNF-1 and NF-Y bind along
the enhancer.
Transcription factors and binding motifs are functionally
important for transcription
Reporter assays in liver hepatoma cells with mutated transcrip-
tion factor binding motifs demonstrate the functional importance of
each site. Following these sequence substitutions, transcription
factor binding motifs were no longer detected by CLOVER
(Table 2). Within the promoter, point mutations in the Sp1 binding
sites decreased the expression of reporter gene by 75% (p,0.005)
and point mutations in the CREB binding site resulted in a 40%
decrease (p,0.005; Figure 7A). Point mutations in the HNF-1 or
NF-Y binding sites, in the enhancer, decreased expression of
luciferase reporter by 50% (p,0.005 for both; Figure 7B).
While these results confirm that each motif is important for
transcription, the functional importance of Sp1 and HNF-1
proteins is demonstrated by co-expression of the proteins with
reporter assay constructs. Co-transfection of Sp1 expression
plasmid with the NAGS promoter (4.10Prom) increases expression
of luciferase more than 50% (P,0.005; Figure 7A) while co-
transfection of HNF-1 expression construct with the enhancer and
minimal TATA promoter (4.23Enh), increases expression of the
reporter gene by 25% (p.0.05; Figure 7B) suggesting that
endogenous Sp1 and, less so, HNF-1 do not saturate their binding
motifs on the transfected reporter plasmids.
Reporter assays to compare the effect of the enhancer in liver,
intestine and lung cells, included data that were normalized to the
reporter expression driven by the NAGS promoter. While the
NAGS enhancer (4.10PromEnh) increased expression of the
reporter gene by 50% in liver derived cells (Figure 2A), expression
of the luciferase gene did not increase in the intestine or lung
derived cells (Figure 8) suggesting that the enhancer may
determine tissue specificity of NAGS expression. When HNF-1
expression plasmid and 4.10PromEnh were co-transfected into
intestine and lung derived cells, transcription was stimulated to
levels that were not significantly different from 4.10PromEnh in
liver cells (p.0.05) (Figure 8). Because intestine and lung derived
cells lack HNF-1 (data not shown), this demonstrated the
importance of HNF-1 and NAGS enhancer for the tissue
specificity of NAGS expression.
Figure 3. Transcription start sites (TSS) are species and tissue specific. TSS identified in the promoter of NAGS by 59RACE analysis (blue
circles), the Database of Transcriptional Start Sites (DBTSS) (green circles) and 59 termination sites of Expressed Sequence Tags (ESTs) from Genbank
(orange circles) were aligned on the DNA sequence 59 of the human (A) and mouse (B) NAGS coding sequence. The arrow indicates the translation
start site.
doi:10.1371/journal.pone.0029527.g003
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sequence of the promoter (A) and enhancer (B) regions were aligned using CLUSTALW alignment software. CLOVER analysis was used to identify
transcription factor binding motifs. Binding sites for C/EBP (green), Sp1 (red), CREB/ATF (pink), AP-2 (purple), HNF-1 (blue), NF-Y (olive), and SMAD 3
(cyan) were highly conserved.
doi:10.1371/journal.pone.0029527.g004
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In this study we used bioinformatic analyses to predict
regulatory regions based on the hypothesis that non-coding
DNA sequences that are highly conserved between species are
important for gene regulation. Multiple pair-wise BLAST
alignments and sequence alignment from the UCSC genome
browser were used to identify two conserved regions within NAGS,
which were determined to be a promoter and an enhancer. The
efficacy of this method was confirmed by successful identification
of the experimentally identified promoter and 26.3 kb enhancer
[25,31], along with three additional highly conserved regions, in
the non-coding region upstream of CPS1. It should be noted that
the high stringency of our BLAST analysis (80% identity and at
least 100 bp of aligned sequence in four or more species) was
selected to identify conserved regions that could support multiple
binding sites where complexes of transcription factors may form
[25,58]. This may have caused us to overlook species specific or
isolated binding motifs, such as the recently identified FXR
binding site [59].
The reporter assay results confirm that the two highly conserved
regions within 1 kb and 3 kb upstream of the translational start
site function as promoter and enhancer, respectively. The
promoter activates expression of the luciferase reporter gene and
we therefore infer that it will activate transcription of NAGS in vivo.
Similarly, the enhancer in either orientation increases expression
of luciferase by approximately 50% relative to the promoter alone,
suggesting that it stimulates NAGS transcription as well. The
relatively small but significant effect of the enhancer could be due
to spacing differences between the genomic NAGS promoter and
enhancer and their spacing in the reporter constructs. Alterna-
tively, while HepG2 cells express transcription factors that we
identified using bioinformatic tools, the NAGS enhancer may bind
additional factors, absent in HepG2 cells, and have larger effect in
vivo than in cultured cells. Another explanation for the relatively
small effect of the NAGS enhancer is the possible presence of a
proximal enhancer within the region we termed the promoter.
Additional experiments are necessary to distinguish between these
two possibilities.
Our analysis of the NAGS transcriptional start sites identified
multiple TSS that may be species and tissue specific. While the
function of each TSS is unknown, these results are consistent with
transcription initiation by Sp1 [16,60,61], and future experiments
may find that they are involved in transcriptional control for tissue
specific expression, developmental-stage specific expression, quan-
titatively different levels of mRNA expression, or may even
determine the transcript stability [62].
After we confirmed that the promoter and enhancer initiate and
increase transcription, we looked for transcription factors that bind
and regulate NAGS in these regions. By filtering for the highly
over-represented and spatially conserved binding sites, relative to
the translational start codon, we identified Sp1, CREB, and C/
EBP in the promoter and HNF-1 AP-2, NF-Y, and SMAD-3 in
the enhancer as transcription factors that could bind to the NAGS
upstream region. This filtering method was confirmed by analysis
of the 26.3 kb enhancer of CPS1 in which binding sites for the
previously published C/EBP, CREB, GR, and HNF-3 were
identified.
The protein-DNA pull down assays, designed to test which
transcription factors among a pool of nuclear proteins bind to
amplified sequence of conserved upstream DNA, confirmed that
Sp1, CREB, HNF-1 and NF-Y bind to NAGS promoter and
enhancer, while we could not detect binding of C/EBP, AP-2 and
SMAD3 (Figure 5). We initially used 60 bp probes encompassing a
specific binding motif for the protein–DNA pull down assays.
However, probes encompassing the entire region were better able
to bind transcription factors (data not shown), suggesting that
binding is facilitated by interactions with DNA sequences outside
Figure 5. DNA-protein avidin-agarose pull-down assay results confirm transcription factor binding. Two probes for the promoter (A)
and one probe for the enhancer (B) encompass the highly conserved transcription factor binding motifs of NAGS. The motif colors reflect the colors
used in figures 4A and B. Assays followed by immunoblot confirmed binding of Sp1 and CREB, but not C/EBP within the promoter (C) and HNF-1 and
NF-Y, but not SMAD3 or AP-2 within the enhancer regions (D). Lanes 1–4 represent precipitated proteins from mouse liver nuclear extract bound to
biotinylated probes of the regions of interest (Lane 1), non-biotinylated probes of the regions of interest (Lane 2), biotinylated probes of non-specific
regions (Lane 3), and no probe (Lane 4). Lanes 5–8 represent supernatant fluid from overnight incubation of biotinylated probes of the region of
interest (Lane 5), non-biotinylated probes of the region of interest (Lane 6), biotinylated probes of the non-specific regions (Lane 7), or no probe (Lane
8). Immunoblots are representative of at least three replicate experiments.
doi:10.1371/journal.pone.0029527.g005
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co-activators. ChIP analysis was used to confirm binding of the
predicted transcription factors to the DNA regions of interest
under physiological conditions. ChIP and DNA-pull down assays
confirmed that Sp1 and CREB bind to the promoter and HNF-1
and NF-Y bind to the enhancer of NAGS (Figures 5 and 6), while
reporter assays demonstrated the functional importance of each
binding motif by a decrease in transcription following mutagenesis
of the binding sites (Figure 7).
Furthermore, we have demonstrated that Sp1 and HNF-1 are
important for stimulation of transcription of NAGS and that HNF-
1 determines tissue specificity of NAGS expression. In the liver
derived cell line, co-transfection of either Sp1 or HNF-1
expression plasmids with reporter constructs containing the NAGS
promoter and enhancer led to increased expression of the reporter
gene (Figure 7) suggesting that these two transcription factors
regulate expression of NAGS in the liver. In the lung and intestine
derived cell lines, expression of HNF-1 was sufficient to activate
expression of reporter gene in constructs containing NAGS
enhancer and promoter (Figure 8). This suggests that HNF-1
binding to the NAGS enhancer determines tissue specificity of
NAGS expression. Testing the effect of over-expression of CREB
protein was hindered by its capacity to homo- and heterodimerize
with multiple partners [63,64]. The effect of NF-Y was not tested
because this transcription factor is a heterotrimer [65] and its co-
expression with reporter plasmids would require stable expression
of NF-Y subunit proteins by in vitro cell culture before reporter
plasmids can be transfected and assayed for NF-Y effect on
transcription.
From the data provided herein, we can speculate on the
potential role these factors play in regulating NAGS transcription.
First, in the absence of a canonical TATA-box, transcription
initiated by Sp1 often results in multiple transcriptional start sites
[66,67]. Sp1 is a strong activator of transcription [16,68,69,70,71]
and when multiple Sp1 sites are present, as in NAGS, multiple Sp1
proteins can form complexes with each other and synergistically
activate transcription [16,69]. Because transcription is significantly
increased by co-expression with Sp1 protein and decreased
Figure 6. Chromatin Immunoprecipitation (ChIP) results confirm transcription factor binding. ChIP with transcription factor antibodies
was compared to negative control IgG antibody. Real-Time PCR using promoter or enhancer specific primers was compared to primers for the
negative locus MIP-2. The results confirmed that Sp1 and CREB but not C/EBP bind within the promoter (A) and HNF-1 and NF-Y but not AP-2 or
SMAD2/3 bind within the enhancer region (B) of NAGS. Calculated error was from three replicate experiments and reported as 6 SEM. One asterisk (*)
indicates p,0.05 and two asterisks (**) indicate p,0.005.
doi:10.1371/journal.pone.0029527.g006
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transcription. Mutagenesis of the putative transcription factor binding sites significantly decreases transcription by the promoter (A) and the
enhancer with TATA promoter (B) in liver derived cells when compared to non-mutated sites. Addition of Sp1 with the promoter (A) and HNF-1 with
the enhancer (B) increases transcription driven by non-mutated constructs. Calculated results are an average of three independent experiments that
were each carried out in triplicate, normalized to Rluc expression, and expressed relative to the promoter for each experiment with error reported as
6SEM. Lowercase letters indicate statistically significant differences.
doi:10.1371/journal.pone.0029527.g007
Figure 8. The NAGS enhancer shows tissue specificity. The enhancer with NAGS promoter (4.10PromEnh) increases transcription relative to the
promoter in liver derived cells but not in intestine or lung derived cells (cyan bars) without the addition of HNF-1 protein (teal bars). Calculated results
are an average of three independent experiments that were carried out in triplicate, normalized to Rluc expression, and expressed relative to the
promoter for each experiment with error reported as 6SEM. Lowercase letters indicate statistically significant differences.
doi:10.1371/journal.pone.0029527.g008
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the activator of NAGS transcription, similar to its role for ASS, ASL
and ARG1 [15,25].
Second, studies have shown that glucagon and second
messenger cAMP trigger a cascade that phosphorylates CREB
and allows for DNA binding and activation of transcription
[72,73]. In CPS1 and ASS, CREB stimulates transcription upon
glucagon signaling [15,31]. Decrease in transcription following
CREB mutation and the close proximity of Sp1 and CREB
binding sites among the TSS suggests that the transcription
initiation machinery may be recruited by these factors, and future
research should examine this postulate.
Our experiments and other studies [74] confirm the role of
HNF-1 in NAGS expression. HNF-1 is essential for stimulation of
NAGS expression by its enhancer. This factor is in part regulated
by HNF-3, HNF-4, and C/EBP, each of which are known to
regulate other urea cycle genes [75,76,77]. Future research will
focus on the mechanism of control between these factors, HNF-1,
and NAGS. Our study has also shown that NF-Y is an activator of
NAGS expression, and future studies will focus on the exact
mechanism of its function in this context.
The human NAGS gene on the forward strand of chromosome
17 partially overlaps with the peptide YY (PYY) gene, which is on
the reverse strand. This overlap was identified with a PYY cDNA
isolated from a brain astrocytoma cDNA library that has an 80
nucleotide long exon located between regions A and B of the
NAGS promoter [78,79] (Figure 1). Other full-length PYY
transcripts initiate about 500 bp upstream of the PYY coding
region, which is located 51 kb upstream of the NAGS translation
initiation codon. Recent analysis of human transcripts revealed
that many protein coding loci are associated with at least one
transcript that initiates from a distal site [80], but the significance
or function of these transcripts remains to be elucidated. Partial
overlap between human NAGS and PYY genes raises the
interesting possibility that these two genes share cis-acting
regulatory elements and might be co-regulated [79,81]. The
mechanism of co-regulation of human NAGS and PYY is likely to
be complex because of their differing tissue expression patterns
[1,82,83,84] including different cell types within the intestine.
PYY is expressed in the intestinal neuroendocrine cells [85,86]
while epithelial cells in the small intestine express NAGS [87,88],
together with OTC and CPS1 [13,89]. Inspection of the
transcription factor binding track of the UCSC genome browser
revealed two binding sites for the CTCF transcription repressor
between NAGS and PYY genes; they are located approximately
9.5 and 21 kb upstream of the NAGS coding region. The CTCF
binding sites could act as chromatin insulators [90,91,92] and
either block regulation of PYY by the NAGS enhancer or enable
cell type specific regulation of each gene by the NAGS enhancer
and promoter. Our results show that the NAGS promoter in the
reverse orientation does not activate transcription of the reporter
gene in liver derived cells (Figure 2), but this does not preclude
transcription activation in other cell types, not tested in this study.
It is possible that the NAGS promoter, enhancer, or other NAGS
regions, regulates expression of PYY [84], and reporter assays in
tissues and cultured cells which express PYY would test this
hypothesis.
While regulation of NAGS b yS p 1 ,C R E B ,H N F - 1 ,N F - Y ,
and factors that regulate them, requires additional study,
identification of regions that regulate human NAGS and OTC
have enabled diagnosis of patients with clinical symptoms of
urea cycle disorders, but lacking disease causing mutations in
the coding regions of the genes [93,94]. Recently, we identified
a patient with a mutation in the enhancer of NAGS and
confirmed the diagnosis of NAGS deficiency by showing that
the mutation significantly decreases transcription of NAGS [93].
This example suggests that identification of regulatory regions
within genes will lead to more and better diagnoses of urea
cycle disorders and other genetic diseases and to accurate
genetic counseling.
In conclusion, this study identified a promoter and a tissue
specific enhancer of NAGS and functionally relevant transcription
factor binding motifs within these regions. The results show that
Sp1 and CREB bind to the NAGS promoter, suggesting that
glucagon and cAMP signaling may regulate the expression of
NAGS. Within the enhancer, HNF-1 may be an important factor
in the coordinated regulation of this urea cycle gene transcription
through its interaction with HNF-3, HNF-4 and C/EBP while the
role of NF-Y is less clear considering that NF-Y may function as an
activator or repressor. While additional studies will be needed to
further define the roles of these factors, these results contain the
first thorough analysis of NAGS and suggest networks of control
between signaling cascades, NAGS and the coordinated regulation
of the other urea cycle genes.
Supporting Information
Figure S1 Regions Upstream of mammalian CPS1 genes
are highly conserved. Three new highly conserved regions
were identified within 15 kb 59 of the CPS1 translational start site.
Conservation algorithms phastCons (green) and phyloP (blue)
from the UCSC genome browser indicate regions that are highly
conserved across all mammals (A). Pair-wise blast analysis of
human, chimpanzee, dog, mouse, and rat 59 non-coding region of
CPS1 were used to identify two known and three previously
unknown regions of high conservation, referred to enhancer/
repressor regions A, B, and C. Highly conserved regions within the
CPS1 59 non-coding sequence include the proximal promoter,
region A, the -enhancer, region B, and region C.
(TIF)
Figure S2 Highly conserved regulatory regions, up-
stream of the mouse Nags gene, function as promoter
and enhancer elements. Mouse promoter (m4.10Prom),
promoter and enhancer (m4.10PromEnh), and enhancer with
TATA promoter (m4.23Enh) stimulated transcription while
enhancer lacking a promoter (m4.10Enh) did not in liver cells.
Calculated results are an average of three independent experi-
ments that were carried out in triplicate, normalized to Rluc
expression, and expressed relative to the promoter for each
experiment with error reported as 6SEM.
(TIF)
Figure S3 Novel transcription factor binding motifs, in
the enhancer region of CPS1, were identified using
CLOVER. Several highly conserved transcription factor binding
sites were present in the enhancer region. An asterisk denotes an
experimentally verified transcription factor binding site. All motifs
were spatially conserved between mammalian species.
(TIF)
Table S1 Sequences of primers that were used to
amplify human or mouse DNA by PCR for insertion of
the promoter and enhancer regions into sequencing and
reporter assay vectors.
(DOCX)
Table S2 Primer sequences used to determine tran-
scription start sites of NAGS with 59 RACE. Primers were
designed according to manufacturer’s instructions and used to
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liver and small intestine RNA using 59 RACE.
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Table S3 Primer sequences used to generate DNA
probes of the specified regions of mNags. Primers were
used to generate DNA probes, by PCR, of the promoter,
enhancer, or non-specific specified regions of mNags.
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Table S4 Primer sequences used for quantitative real-
time PCR analysis of chromatin immunoprecipitation
samples.
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Table S5 Results of CLOVER analysis of the enhancer
region with sequence information for human and mouse
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factors that are not expressed in the liver.
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Table S6 Results of CLOVER analysis of the promoter
region with sequence information for human and mouse
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Table S7 Results of CLOVER analysis of the enhancer
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